Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Ardern-Jones, Michael R. [2 ,3 ]
Bieber, Thomas [4 ]
Hong, Chih-Ho [5 ,6 ,7 ]
Chu, Chia-Yu [8 ,9 ]
Liu, Meng [10 ]
Yang, Yang [10 ]
Ladizinski, Barry [10 ]
Teixeira, Henrique D. [10 ]
Calimlim, Brian M. [10 ]
Thyssen, Jacob P. [11 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Univ Hosp Southampton NHS Fdn Trust, Southampton Gen Hosp, Dept Dermatol, Southampton, Hants, England
[3] Univ Southampton, Clin Expt Sci, Fac Med, Southampton, Hants, England
[4] Univ Bonn, Dept Dermatol & Allergy, Bonn, Germany
[5] Dr Chih ho Hong Med Inc, Surrey, BC, Canada
[6] Univ British Columbia, Dept Dermatol & Skin Sci, Vancouver, BC, Canada
[7] Prob Med Res, Surrey, BC, Canada
[8] Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan
[9] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[10] AbbVie Inc, N Chicago, IL USA
[11] Herlev & Gentofte Hosp, Dept Dermatol & Allergy, Hellerup, Denmark
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
28032
引用
收藏
页码：AB171 / AB171
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: results from the pivotal phase III, randomized, double-blind, placebo-controlled AD Up study
    Reich, K.
    Teixeira, H. D.
    De Bruin-Weller, M.
    Bieber, T.
    Soong, W.
    Kabashima, K.
    Werfel, T.
    Zeng, J.
    Huang, X.
    Hu, X.
    Ladizinski, B.
    Chu, A. D.
    Silverberg, J. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E59 - E60
  • [42] Effects of upadacitinib on the patient-reported impact of atopic dermatitis: Atopic Dermatitis Impact Scale (ADerm-IS) - results from two pivotal phase III studies (MEASURE UP 1 and MEASURE UP 2)
    Simpson, E. L.
    De Bruin-Weller, M. S.
    Prajapati, V. H.
    Calimlim, B. M.
    Teixeira, H. D.
    Zeng, J.
    Liu, M.
    Silverberg, J. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E124 - E124
  • [43] Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies
    Kabashima, K.
    Matsumura, T.
    Komazaki, H.
    Kawashima, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 642 - 651
  • [44] Effects of upadacitinib on patient-reported symptoms of atopic dermatitis: Atopic Dermatitis Symptom Scale (ADerm-SS) - results from two pivotal phase III studies (MEASURE UP 1 and MEASURE UP 2)
    Silverberg, J. I.
    Thyssen, J. P.
    Rosmarin, D.
    Pink, A. E.
    Calimlim, B. M.
    Teixeira, H. D.
    Hu, X.
    Yang, Y.
    Thaci, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E124 - E125
  • [45] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial (vol 397, pg 2169, 2021)
    Reich, K.
    Teixeira, H. D.
    de Bruin-Weller, M.
    LANCET, 2021, 398 (10302): : 746 - 746
  • [46] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial (vol 397, pg 2169, 2021)
    Reich, K.
    Teixeira, H. D.
    de Bruin-Weller, M.
    LANCET, 2021, 397 (10292): : 2336 - 2336
  • [47] EFFECT OF UPADACITINIB ON INTENSITY OF SCORAD ITEMS AND IMPACTS TO ITCH AND SLEEP: ANALYSIS FROM THE MEASURE UP 1 AND MEASURE UP 2 STUDIES
    Cameron, Michael
    Magnolo, Nina
    Prajapati, Vimal H.
    Haque, Adel
    Lee, Wan-Ju
    Altman, Katherine
    Platt, Andrew M.
    Lane, Michael C.
    Calimlim, Brian M.
    Taieb, Alain
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 56 - 57
  • [48] Dupilumab Treatment Results in Rapid Improvement in Itch in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (LIBERTY AD SOLO 1 & 2, and ADOL trials)
    Yosipovitch, Gil
    Hong, Chih-ho
    Simpson, Eric
    Eckert, Laurent
    Chen, Zhen
    Mina-Osorio, Paola
    Gadkari, Abhijit
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB190 - AB190
  • [49] Maintenance of efficacy and safety with lebrikizumab up to one year of treatment in patients with moderate-to-severe atopic dermatitis with or without topical corticosteroids
    Guttman-Yassky, E.
    Weidinger, S.
    Silverberg, J.
    Gooderham, M.
    Thyssen, J.
    Irvine, A.
    Elmaraghy, H.
    Natalie, C.
    Hu, C.
    Pierce, E.
    Gil, E. G.
    Simpson, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S348 - S348
  • [50] Efficacy and safety of dupilumab with concomitant topical corticosteroids for up to 1 year in moderate-to-severe atopic dermatitis: a randomized, placebo-controlled phase III trial (CHRONOS)
    Blauvelt, A.
    Gooderham, M.
    Foley, P.
    Griffiths, C. E. M.
    Cather, J. C.
    de Bruin-Weller, M.
    Soo, Y.
    Akinlade, B.
    Graham, N. M. H.
    Pirozzi, G.
    Shumel, B.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 10 - 10
12345